Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
11
2018
accepted:
05
02
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
22
11
2019
Statut:
epublish
Résumé
Hepatic stellate cells (HSCs) were reported to promote the progression of hepatocellular carcinoma (HCC), however its mechanism is uncertain. We previously reported that protein kinase R (PKR) in hepatocytes regulated HCC proliferation. In this study, we focused on the role of PKR in HSCs, and clarified the mechanism of its association with HCC progression. We confirmed the activation of PKR in a human HSC cell line (LX-2 cell). IL-1β is produced from HSCs stimulated by lipopolysaccharide (LPS) or palmitic acid which are likely activators of PKR in non-alcoholic steatohepatitis (NASH). Production was assessed by real-time PCR and ELISA. C16 and small interfering RNA (siRNA) were used to inhibit PKR in HSCs. The HCC cell line (HepG2 cell) was cultured with HSC conditioning medium to assess HCC progression, which was evaluated by proliferation and scratch assays. Expression of PKR was increased and activated in stimulated HSCs, and IL-1β production was also increased molecular. Key molecules of the mitogen-activated protein kinase pathway were also upregulated and activated by LPS. Otherwise, PKR inhibition by C16 and PKR siRNA decreased IL-1β production. HCC progression was promoted by HSC-stimulated conditioning medium although it was reduced by the conditioning medium from PKR-inhibited HSCs. Moreover, palmitic acid also upregulated IL-1β expression in HSCs, and conditioning medium from palmitic acid-stimulated HSCs promoted HCC proliferation. Stimulated HSCs by activators of PKR in NASH could play a role in promoting HCC progression through the production of IL-1β, via a mechanism that seems to be dependent on PKR activation.
Identifiants
pubmed: 30794626
doi: 10.1371/journal.pone.0212589
pii: PONE-D-18-32583
pmc: PMC6386440
doi:
Substances chimiques
IL1B protein, human
0
Interleukin-1beta
0
Neoplasm Proteins
0
EIF2AK2 protein, human
EC 2.7.11.1
eIF-2 Kinase
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212589Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2015 Dec 04;10(12):e0144295
pubmed: 26636761
Am J Anat. 1971 Dec;132(4):429-62
pubmed: 4942297
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Nature. 2012 Aug 30;488(7413):670-4
pubmed: 22801494
Hepatology. 2011 Jul;54(1):133-44
pubmed: 21488066
Cancer Sci. 2011 Aug;102(8):1522-31
pubmed: 21564420
J Hepatol. 2017 Nov;67(5):1104-1105
pubmed: 28939135
Biochem Biophys Res Commun. 2016 Jan 29;470(1):15-21
pubmed: 26682925
Med Res Rev. 2017 Jan;37(1):180-216
pubmed: 27604144
J Biol Chem. 2000 Jan 28;275(4):2247-50
pubmed: 10644669
Life Sci. 2017 May 1;176:42-53
pubmed: 28322865
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
Lab Invest. 2014 May;94(5):491-502
pubmed: 24566933
J Hepatol. 2014 Jun;60(6):1306-9
pubmed: 24530649
Semin Liver Dis. 2010 Aug;30(3):232-44
pubmed: 20665376
Hepatology. 2015 Feb;61(2):585-97
pubmed: 25294684
PLoS One. 2017 May 2;12(5):e0176793
pubmed: 28463985
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S80-9
pubmed: 25755616
PLoS One. 2013 Jul 02;8(7):e67750
pubmed: 23844083
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53
pubmed: 27785449
Sci Rep. 2016 Apr 26;6:25013
pubmed: 27113095
J Gastroenterol. 2015 Mar;50(3):350-60
pubmed: 24929638
J Gastroenterol. 2017 Aug;52(8):940-954
pubmed: 28062946
Hepatology. 2010 Jul;52(1):360-9
pubmed: 20578152
Liver Int. 2014 Jul;34(6):834-43
pubmed: 24397349
Annu Rev Pharmacol Toxicol. 2005;45:605-28
pubmed: 15471534
PLoS One. 2016 Apr 05;11(4):e0153118
pubmed: 27046197
Cell Death Dis. 2018 Jan 18;9(2):22
pubmed: 29348414
J Clin Invest. 2009 Nov;119(11):3213-25
pubmed: 19855130
PLoS Pathog. 2013;9(4):e1003330
pubmed: 23633957
J Med Virol. 2007 Aug;79(8):1120-7
pubmed: 17596833
Gastroenterology. 2013 Mar;144(3):512-27
pubmed: 23313965
Am J Gastroenterol. 2003 Nov;98(11):2528-34
pubmed: 14638359
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Gastroenterol Clin Biol. 1997;21(11):869-79
pubmed: 9587539
J Hepatol. 2011 Dec;55(6):1391-9
pubmed: 21703208
Cancer Sci. 2018 Apr;109(4):919-925
pubmed: 29478262